Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis

por Benson, Merrill D, Ackermann, Elizabeth J, Monia, Brett P
Publicado 2015

The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods...

por Bergemann, Rito, Ackermann, Elizabeth, Monia, Brett, Shenker, Andrew, Dyck, Peter
Publicado 2015

A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy

por Millns, Helen, Bergemann, Rito, Ackermann, Elizabeth, Monia, Brett, Lukas, Mary Ann
Publicado 2015

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

por Yu, Rosie Z., Collins, Jon W., Hall, Shannon, Ackermann, Elizabeth J., Geary, Richard S., Monia, Brett P., Henry, Scott P., Wang, Yanfeng
Publicado 2020

Burden of hereditary transthyretin amyloidosis on quality of life

por Yarlas, Aaron, Gertz, Morie A., Dasgupta, Noel R., Obici, Laura, Pollock, Michael, Ackermann, Elizabeth J., Lovley, Andrew, Kessler, Asia Sikora, Patel, Pankaj A., White, Michelle K., Guthrie, Spencer D.
Publicado 2019

Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells

por Niemietz, Christoph J., Sauer, Vanessa, Stella, Jacqueline, Fleischhauer, Lutz, Chandhok, Gursimran, Guttmann, Sarah, Avsar, Yesim, Guo, Shuling, Ackermann, Elizabeth J., Gollob, Jared, Monia, Brett P., Zibert, Andree, Schmidt, Hartmut H. -J.
Publicado 2016

Breast cancer risk and genetic ancestry: a case–control study in Uruguay

por Bonilla, Carolina, Bertoni, Bernardo, Hidalgo, Pedro C, Artagaveytia, Nora, Ackermann, Elizabeth, Barreto, Isabel, Cancela, Paula, Cappetta, Mónica, Egaña, Ana, Figueiro, Gonzalo, Heinzen, Silvina, Hooker, Stanley, Román, Estela, Sans, Mónica, Kittles, Rick A
Publicado 2015

mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis

por Dyck, P. James B., Kincaid, John C., Wiesman, Janice F., Polydefkis, Michael, Litchy, William J., Mauermann, Michelle L., Ackermann, Elizabeth J., Guthrie, Spencer, Pollock, Michael, Jung, Shiangtung W., Baker, Brenda F., Dyck, Peter J.
Publicado 2020

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis

por Dyck, P. James B., Coelho, Teresa, Waddington Cruz, Marcia, Brannagan, Thomas H., Khella, Sami, Karam, Chafic, Berk, John L., Polydefkis, Michael J., Kincaid, John C., Wiesman, Janice F., Litchy, William J., Mauermann, Michelle L., Ackermann, Elizabeth J., Baker, Brenda F., Jung, Shiangtung W., Guthrie, Spencer, Pollock, Michael, Dyck, Peter J.
Publicado 2020

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

por Coelho, Teresa, Yarlas, Aaron, Waddington-Cruz, Marcia, White, Michelle K., Sikora Kessler, Asia, Lovley, Andrew, Pollock, Michael, Guthrie, Spencer, Ackermann, Elizabeth J., Hughes, Steven G., Karam, Chafic, Khella, Sami, Gertz, Morie, Merlini, Giampaolo, Obici, Laura, Schmidt, Hartmut H., Polydefkis, Michael, Dyck, P. James B., Brannagan III, Thomas H., Conceição, Isabel, Benson, Merrill D., Berk, John L.
Publicado 2019